LZB vs LBRX Comparison

La-Z-Boy Inc is a world'wide producer of reclining chairs and one of the manufacturers/distributors of residential furniture in the United States. It manufacture, market, import, export, distribute and retail upholstery furniture products. In addition, it import, distribute and retail accessories and casegoods (wood) furniture products. Its reportable operating segments include the Retail segment and the Wholesale segment. Its Retail segment mainly sells upholstered furniture. Wholesale segment manufactures and imports upholstered and casegoods (wood) furniture and sells directly. The company generates majority of revenue from Wholesale segment which manufactures and imports upholstered furniture, such as recliners and motion furniture, sofas, loveseats, chairs, sectionals, modulars, etc.

LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.